Lead Poisoning in a 3-Year-Old: Etiology & Workup

1. Etiology / Sources of Lead Exposure in Young Children

Environmental / Household

Ingested / Product-Related

Occupational / Secondary (Take-home lead)

• Parent working in battery recycling, radiator repair, auto mechanics, construction/demolition
• Lead brought home on clothing, shoes, or hands

Other

• Retained foreign body (e.g., bullet fragment, fishing sinker ingested or embedded)
• Burning painted wood or batteries for fuel (low-income settings)

— Robbins Pathologic Basis of Disease: "For most of the twentieth century the major sources of lead in the environment were lead-containing house paints and gasoline."

— Henry's Clinical Diagnosis: "Lead poisoning is seen in children in large cities who consume lead in the form of paint (pica)."

2. Pathophysiology: ALA → Protoporphyrin Conversion (The Key Enzymatic Block)

Normal Heme Biosynthesis Pathway

ALA synthetase
Glycine + Succinyl-CoA ──────────────► δ-ALA (delta-aminolevulinic acid)
                                          ↓
                           δ-ALA dehydratase (ALAD) ← [BLOCKED BY LEAD]
                                          ↓
                                    Porphobilinogen
                                          ↓
                           (multiple steps) → Coproporphyrinogen III
                                          ↓
                                    Protoporphyrin IX
                                          ↓
                           Ferrochelatase ← [BLOCKED BY LEAD]
                           (Fe²⁺ + Protoporphyrin IX → Heme)

1. δ-ALA dehydratase (ALAD) — prevents ALA → porphobilinogen conversion → ALA accumulates in urine
2. Ferrochelatase — prevents iron insertion into protoporphyrin IX → protoporphyrin accumulates, zinc substitutes → zinc protoporphyrin (ZPP) forms instead of heme

— Henry's Clinical Diagnosis: "Lead blocks the action of β-ALA synthetase, δ-ALA dehydratase (ALAD), coproporphyrinogen decarboxylase, and ferrochelatase, producing anemia."

— Robbins Basic Pathology: "Zinc-protoporphyrin (ZPP) is formed instead of heme, leading to decreased iron incorporation into heme and subsequent anemia."

3. Workup for a 3-Year-Old with Verbal Delay (to Exclude Lead Toxicity as Cause)

First-Line: Blood Lead Level (BLL)

• Whole blood lead measured by atomic absorption spectroscopy or ICP/MS
• Reference & action thresholds (CDC/AAP):
  • < 3.5 µg/dL — current CDC reference value (updated 2021; previously 5 µg/dL)
  • ≥ 3.5 µg/dL — requires follow-up
  • ≥ 45 µg/dL — chelation therapy indicated
  • ≥ 70 µg/dL — medical emergency
• BLL reflects recent exposure; short half-life (~35 days in blood)

Heme Pathway Markers (confirming ALA → Protoporphyrin block)

— Henry's Clinical Diagnosis: "Increased amounts of ALA in urine, decreased ALAD activity in red blood cells, increased amounts of free erythrocyte protoporphyrin, and elevated amounts of zinc protoporphyrin are found with inorganic lead poisoning. The assay for zinc protoporphyrin is a particularly simple fluorometric one that is widely used and is an excellent screening test for frank lead toxicity. However, the test is not sensitive to the low blood lead levels now regarded as harmful."

— Robbins Basic Pathology: "Elevated blood lead, red cell free protoporphyrin, or zinc-protoporphyrin levels are required for definitive diagnosis."

Complete Blood Count (CBC)

• Microcytic, hypochromic anemia
• Basophilic stippling of RBCs — classic, but not pathognomonic
• Hemolysis markers if indicated

Imaging

• Long bone X-rays (wrist/knee) — "lead lines" at growth plates (radiopaque bands at physis); indicates chronic exposure
• Abdominal X-ray — if pica suspected, to identify ingested paint chips or foreign bodies

Renal Function

• Urinalysis: albuminuria, hematuria (proximal tubular damage)
• BMP/CMP: creatinine

Neurodevelopmental Assessment (directly relevant to verbal delay)

• Formal developmental evaluation (Bayley Scales, ADOS, speech-language assessment)
• Lead neurotoxicity causes: reduced IQ, learning disabilities, retarded psychomotor development, verbal/language delay; these CNS effects in children are usually irreversible

Environmental Assessment

• Detailed environmental history: housing age, renovation, water source, parental occupation, dietary history, folk medicine use, pica behavior
• Home lead inspection / EPA-certified lead assessment if indicated

Summary Table: Heme Pathway Workup

Note on verbal delay: At blood lead levels as low as 10 µg/dL (now considered harmful), cognitive and language delays occur without overt encephalopathy. The ZPP/FEP tests may be normal at these levels — BLL remains the only reliable screen for low-level neurotoxic exposure.

— Robbins Pathologic Basis: "Effects of chronic lead exposure in children may be subtle, producing mild dysfunction, including reduced IQ, learning disabilities, and delayed psychomotor development."

JAK2 Kinase

What Is JAK2?

The JAK-STAT Signaling Pathway (Normal Function)

1. Cytokine/growth factor (e.g., erythropoietin, thrombopoietin, IL-2, IL-3) binds its receptor
2. Receptor dimerizes → JAK2 molecules (constitutively associated with the receptor) transphosphorylate each other (activation)
3. Activated JAK2 phosphorylates the cytokine receptor → creates docking sites for STAT proteins (Signal Transducers and Activators of Transcription)
4. JAK2 phosphorylates STATs → they dimerize and translocate to the nucleus → activate target genes (proliferation, differentiation, anti-apoptosis)
5. JAK2 also activates the Ras/Raf/MAP kinase and PI3K/AKT pathways in parallel
6. SOCS (Suppressor of Cytokine Signaling) proteins are induced as negative feedback to shut JAK2 off

• Erythropoietin (EPO) → red cell production
• Thrombopoietin (TPO/MPL) → platelet production
• G-CSF, GM-CSF → granulopoiesis
• Growth hormone, prolactin, leptin

JAK2 Mutations in Disease: The V617F Mutation

• Located in the JH2 pseudokinase (autoinhibitory) domain
• Normally JH2 suppresses JH1 kinase activity; the V617F substitution disrupts this autoinhibition → constitutive (ligand-independent) kinase activation
• Results in continuous signaling through JAK-STAT even without growth factor binding
• Hematopoietic progenitors become EPO-independent — they proliferate without needing erythropoietin

— Tietz Textbook of Laboratory Medicine: "The JAK2 p.Val617Phe mutation occurs in the autoinhibitory pseudokinase (JH2) domain of JAK2 and imparts dysregulated kinase activity... polycythemia vera progenitor cells are abnormally EPO independent."

Disease Associations

— Robbins Pathologic Basis of Disease: Mutations in JAK2, CALR, and MPL all result in constitutive tyrosine kinase activation in myeloproliferative neoplasms.

Clinical Use: JAK2 V617F Testing

• Diagnostic test for suspected myeloproliferative neoplasms (MPNs)
• Distinguishes neoplastic from reactive causes of erythrocytosis/thrombocytosis
• Detected by: allele-specific PCR, pyrosequencing, next-generation sequencing (NGS) myeloid panels
• A positive result is a WHO diagnostic criterion for PV, ET, and PMF

JAK2 Inhibitors (Therapeutic Targeting)

— Tietz: "Ruxolitinib treatment reduced patient spleen size and improved the overall burden of symptoms... JAK2 inhibitor therapy markedly improves quality of life of MPN patients but, in contrast to imatinib in CML, may not improve overall survival."

Summary